PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jbcThe Journal of Biological Chemistry
 
J Biol Chem. 2013 May 31; 288(22): 15520–15531.
Published online 2013 April 16. doi:  10.1074/jbc.M113.459792
PMCID: PMC3668713

Control of Adipogenesis by the Autocrine Interplays between Angiotensin 1–7/Mas Receptor and Angiotensin II/AT1 Receptor Signaling Pathways*An external file that holds a picture, illustration, etc.
Object name is sbox.jpg

Abstract

Angiotensin II (AngII), a peptide hormone released by adipocytes, can be catabolized by adipose angiotensin-converting enzyme 2 (ACE2) to form Ang(1–7). Co-expression of AngII receptors (AT1 and AT2) and Ang(1–7) receptors (Mas) in adipocytes implies the autocrine regulation of the local angiotensin system upon adipocyte functions, through yet unknown interactive mechanisms. In the present study, we reveal the adipogenic effects of Ang(1–7) through activation of Mas receptor and its subtle interplays with the antiadipogenic AngII-AT1 signaling pathways. Specifically, in human and 3T3-L1 preadipocytes, Ang(1–7)-Mas signaling promotes adipogenesis via activation of PI3K/Akt and inhibition of MAPK kinase/ERK pathways, and Ang(1–7)-Mas antagonizes the antiadipogenic effect of AngII-AT1 by inhibiting the AngII-AT1-triggered MAPK kinase/ERK pathway. The autocrine regulation of the AngII/AT1-ACE2-Ang(1–7)/Mas axis upon adipogenesis has also been revealed. This study suggests the importance of the local regulation of the delicately balanced angiotensin system upon adipogenesis and its potential as a novel therapeutic target for obesity and related metabolic disorders.

Keywords: Adipocyte, Adipogenesis, Angiotensin, Angiotensin II, Obesity, Ang(1–7)

Introduction

The renin-angiotensin system (RAS)2 critically regulates homeostasis in various body systems (1, 2). Angiotensin II (AngII), the major bioactive component of RAS, is converted from the precursor molecule angiotensinogen through two-step hydrolysis by renin and angiotensin-converting enzyme (ACE) (2). It acts through AngII type 1 (AT1) and AngII type 2 (AT2) receptors (3). AngII can be further hydrolyzed by ectoenzyme ACE2 into Ang(1–7) (4). Mediated by its interaction with the G-protein-coupled receptor Mas (Mas receptor) (5), Ang(1–7) usually antagonizes AngII actions (6).

RAS is also a crucial regulator of energy metabolism, implicated in metabolic disorders such as obesity and insulin resistance (79). Adipose tissue, a highly active metabolic and endocrine organ, is a source of components of the RAS (10, 11). On the other hand, AngII receptors and Mas receptors are co-expressed on adipocytes, implying the involvement of the local RAS system in regulating adipocyte functions (12, 13). Several lines of evidence have supported this emerging hypothesis. In particular, recent investigations have begun to reveal that ACE-AngII-AT1 signaling and ACE2-Ang(1–7)-Mas signaling regulate various functions of adipocytes in an intriguing counteractive manner (6). For example, it has been demonstrated that AngII-AT1 inhibits lipolysis and insulin-induced glucose uptake in adipocytes (14, 15), whereas Ang(1–7)-Mas does the opposite (16, 17). Also, AngII-AT1 induces oxidative stress in adipocytes (18), whereas Ang(1–7)-Mas interaction suppresses it (17).

Previous studies have established the inhibitory effects of AngII-AT1 on adipogenesis (1921). We hypothesize that ACE2-Ang(1–7)-Mas acts as an autocrine balancer (feedback route) to promote adipogenesis. We aim, for the first time, to reveal the molecular mechanisms underlying Ang(1–7)-Mas regulation upon adipogenesis and its cross-talk with AngII-AT1 pathways.

EXPERIMENTAL PROCEDURES

Cell Culture and Differentiation

Human subcutaneous preadipocytes (SP-F-2; Zen-Bio Inc.), collected from non-diabetic male subjects (with body mass index of 25–29.9), were grown until confluence (5% CO2 and 37 °C) in preadipocyte growth medium (DMEM/F-12 medium (1:1, v/v) containing 15 mm HEPES, 2 mm l-glutamine, 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 mg/ml streptomycin). Adipocyte differentiation was then induced (defined as day 0) similarly as reported previously (22, 23). Briefly, the cells were treated with adipocyte growth medium (serum-free DMEM/Ham's F-12 medium containing 15 mm HEPES, 2 mm l-glutamine, 33 μm biotin, 17 μm pantothenate, 10 μg/ml transferrin, 0.2 nm triiodothyronine, 100 units/ml penicillin, and 100 mg/ml streptomycin) supplemented with 0.5 μg/ml insulin, 1 μm dexamethasone, 0.5 mm 3-isobutyl-1-methylxanthine, and 10 μm rosiglitazone. After 48 h (on day 2), the medium was replaced with adipocyte growth medium containing insulin and dexamethasone, and thereafter, the medium was refreshed every 2 days for the following 8–10 days.

The 3T3-L1 mouse preadipose cell line (American Type Culture Collection, Manassas, VA) was cultured in DMEM supplemented with 10% (v/v) bovine calf serum, 100 units/ml penicillin, 100 mg/ml streptomycin in a 5% CO2 humidified atmosphere at 37 °C. Adipocyte differentiation of 3T3-L1 cells follows the previously established protocol (24, 25). Specifically, 2 days after the cells became confluent, adipocyte differentiation was induced (defined as day 0) by incubation with DMEM and 10% FBS, 5 μg/ml insulin, 1 μm dexamethasone, and 0.5 mm 3-isobutyl-1-methylxanthine. On day 2 of differentiation, DMEM containing 10% FBS and 5 μg/ml insulin was used as the culture medium. On day 4, the medium was then changed to DMEM with 10% FBS only, and thereafter, the medium was refreshed every 2 days for the following 2–4 days.

In some experiments, 10 μm LY294002, 50 μm PD98059, 100 nm PMA, 10 μm A779, 10 μm PD123319, 10 μm ZD7155, 1 μm AngII, or various concentrations of Ang(1–7) were added to the culture medium. In some experiments, a 30-min pretreatment of LY294002 or 60-min pretreatment of PD98059 was performed prior to the induction of differentiation. Ang(1–7), AngII, ZD7155, and PD123319 were purchased from Tocris Bioscience, and A779 was purchased from GenWay Biotech Inc. All cell culture media, supplements, and sera were purchased from Invitrogen. All other chemicals and reagents were purchased from Sigma-Aldrich.

siRNA Silencing

Gene silencing of Mas receptor (Mas1), ACE2 (Ace2), AT1 (Agtr1), AT2 (Agtr2), ERK1 (Mapk3), ERK2 (Mapk1), or Akt (Akt1 and Akt2) in 3T3-L1 cells was achieved using a mouse MAS1 siRNA (sc62601, Santa Cruz Biotechnology, Inc. (Santa Cruz, CA)), a mouse ACE2 siRNA (sc-41401, Santa Cruz Biotechnology, Inc.), a mouse AT1 siRNA (sc29751, Santa Cruz Biotechnology, Inc.), a mouse AT2 siRNA (sc29753, Santa Cruz Biotechnology, Inc.), mouse ERK1 and ERK2 siRNAs (sc-29308 and sc-35336, Santa Cruz Biotechnology, Inc.), and a mouse Akt siRNA (sc-43610, Santa Cruz Biotechnology, Inc.), respectively. Transfection was done as described previously (26, 27). Specifically, 1 day after being split, the cells were incubated with Opti-MEM (Invitrogen) containing a complex of Lipofectamine-RNAiMAX transfection reagent (0.5% (v/v); Invitrogen) with siRNAs (20 nm) for 4 h, followed by the addition of an equal amount of DMEM containing 20% bovine calf serum and incubation for another 8–12 h. The cells were then maintained in DMEM containing 10% bovine calf serum until confluence, and adipocyte differentiation was initiated as described above.

Confocal Fluorescence Microscopy

Cells grown on glass coverslips were fixed with 3.7% formaldehyde in PBS for 15 min at room temperature and then washed with PBS three times. After being blocked with 1% bovine albumin (BSA) in PBST (PBS with 0.1% Tween 20) at room temperature for 1 h, the cells were incubated (at 4 °C) overnight with goat anti-Mas IgG in PBST with 1% BSA. After washing with PBS three times, the cells were incubated in FITC-labeled anti-goat IgG for 1 h at room temperature in the dark, followed by washing with PBS three times. Fluorescence signals were visualized on a confocal laser-scanning microscope (LSM 510 Meta, Carl Zeiss GmbH).

Western Blot Analysis

The cells were washed twice with ice-cold phosphate-buffered saline (PBS) and then scraped in radioimmune precipitation assay lysis buffer (sc-24948, Santa Cruz Biotechnology, Inc.) containing freshly added protease/phosphatase inhibitor mixture (Cell Signaling Technology). After centrifugation at 4 °C, the supernatant of the sample was collected, and its protein content was determined using a protein assay kit (Bio-Rad) based on the Bradford method. Each cell lysate with an equal amount of protein content (as the loading control) was separated on SDS-PAGE by electrophoresis, followed by transfer onto a nitrocellulose membrane. After blocking the membrane for 2–3 h in TBST (Tris-buffered saline-Tween; 10 mm Tris, 150 mm NaCl, and 0.05% Tween 20, pH 7.4) containing 5% BSA (Sigma), the membrane was incubated with primary antibodies (1:200–400 dilution) in TBST with 1% BSA overnight. After washing three times with TBST buffer, the membrane was subsequently incubated with horseradish peroxidase-conjugated secondary antibodies (1:2000–3000 dilution) for 6–8 h. The protein bands were detected in a G:BOX Chemi XT4 imaging system (Syngene) by using SuperSignal West Pico chemiluminescent substrate (Thermo Scientific).

Antibodies against peroxisome proliferator-activated receptor γ (PPARγ) (sc7196), phospho-PPARγ (sc28001), C/EBPα (sc61), aP2 (A-FABP; sc18661), FAS (sc20140), AT1 (sc31181), AT2 (sc9040), MAS1 (sc54848), ACE2 (sc20998), Akt (sc8312), and phospho-Akt (Ser473) (sc135651) were purchased from Santa Cruz Biotechnology, Inc. Antibody against ACC (3662) was purchased from Cell Signaling Technology. Antibodies against phospho-ERK1/2 (3441-100) and ERK1/2 (3085-100) were purchased from Biovision Inc.

Oil Red O Staining

Lipid droplets in adipocytes were stained with Oil Red O (Sigma-Aldrich) as described previously (28). Briefly, after being fixed in 10% formalin for 60 min, the cells were washed twice with PBS and stained with filtered Oil Red O solution (1.8 mg/ml Oil Red O and 60% (v/v) isopropyl alcohol in distilled water) for 60 min. The cells were then thoroughly washed with distilled water before being photographed under an optical microscope.

Triglyceride Assay

Cellular triglyceride content was determined by using an adipogenesis assay kit (Biovision Inc.) according to the manufacturer's protocol. Briefly, after a 6–8-day differentiation of 3T3-L1 cells, or a 10–12-day differentiation of human preadipocytes, cells were washed twice with PBS, scraped, sonicated to homogenize the suspension, and then assayed for total triglyceride. The total protein concentration, which was used as an internal control, in these cells was measured with a protein assay kit from Bio-Rad.

Enzyme-linked Immunosorbent Assay (ELISA)

The concentration of Ang(1–7) or AngII in the medium was determined using a mouse Ang(1–7) ELISA kit (CSB-E13763m; Cusabio Biotech) or a mouse AngII ELISA kit (CSB-E04495m; Cusabio Biotech), respectively. Each sample contains the same amount of protein (determined by the Bradford method as the internal control of the total cell number).

Statistical Analysis

Data were analyzed using Student's t test and expressed as mean ± S.E. p < 0.05 was considered statistically significant.

RESULTS

Ang(1–7)-Mas Receptor Promotes Adipogenesis and Antagonizes the Antiadipogenic Effect of AngII-AT1 Receptor in Human Preadipocytes

Preadipocytes isolated from human adipose tissue are used here as the in vitro cell model for adipogenesis (29, 30). It has been known that AngII receptors are expressed in preadipocytes, and the majority of AngII receptors found in human preadipocytes and adipocytes are of the AT1 subtype (13, 31) (supplemental Fig. S1). Here, we report that Mas receptors are also expressed in human preadipocytes and adipocytes (Fig. 1A and supplemental Fig. S1). To evaluate the roles of Ang(1–7) and AngII in adipogenesis, human preadipocytes were induced to differentiate in the presence of Ang(1–7) and/or AngII.

FIGURE 1.
Ang(1–7)-Mas receptor enhances adipogenesis and antagonizes the antiadipogenic effect of AngII in human preadipocytes. A, confocal images of immunostained Mas receptors in human preadipocyte and adipocyte. Scale bars, 10 μm. B, representative ...

Transformation of preadipocytes into mature adipocytes requires the coordinated regulation of various transcriptional factors (30). Among them, PPARγ is considered as the most essential one (32). Because adipogenesis is accompanied by lipogenesis, enzymes responsible for lipogenesis (e.g. fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC)) are also regarded as the important markers for adipogenesis (24, 33).

After 10–12 days of hormone-induced differentiation, many of the fibroblast-like spindle-shaped human preadipocytes were differentiated into mature adipocytes, as evidenced by their morphological change and intracellular accumulation of lipid droplets (Fig. 1B). Lipid accumulation, an indicator of the extent of adipogenesis, can be assessed visually by Oil Red O staining of lipid droplets and quantitatively by direct measurement of intracellular triglyceride (TG) content. As shown in Fig. 1, C and D, exogenous application of Ang(1–7) during differentiation considerably increased Oil Red O staining and TG content, and the number of lipid-laden adipocytes was also increased by Ang(1–7) treatment (Fig. 1E and supplemental Fig. S2A). Consistently, the addition of Ang(1–7) enhanced the expression of adipogenic transcriptional factor PPARγ, lipogenesis markers (FAS and ACC), and adipocyte protein-2 (aP2; a specific late marker of adipogenesis (24)) (Fig. 1, F–J). Clearly, Ang(1–7) stimulates the adipocytic differentiation of human preadipose cells.

It has been reported that AngII suppresses adipogenesis of human preadipocytes via the AT1 receptor (19, 20). As expected, the addition of AngII during differentiation suppressed adipogenesis, as evidenced by reduced Oil Red O staining, TG content, the number of adipocytes, and the expression of adipogenesis markers (PPARγ, FAS, ACC, and aP2) (Fig. 1). Such AngII-induced suppression is mediated by AT1 receptors because it can be rectified by a specific AT1 antagonist (ZD7155) (34) but not by a specific inhibitor of AT2 (PD123319) (35) (supplemental Fig. S2B).

Interestingly, co-incubation with Ang(1–7) effectively abolished the antiadipogenic effects of AngII (Fig. 1). To determine if Ang(1–7) mediates its stimulatory actions through the Mas receptor, the selective Mas receptor antagonist A779 (36) was applied during differentiation. As shown in Fig. 1, the addition of A779 completely eliminated the stimulatory effects of Ang(1–7) on adipogenesis and its counteraction on AngII. Taken together, we conclude that Ang(1–7), via its interaction with the Mas receptor, not only stimulates adipogenesis but also counteracts the antiadipogenic effect of AngII.

The Adipogenic Effect of Ang(1–7) and Its Counteraction against AngII-AT1 Activation Are Confirmed in 3T3-L1 Preadipocytes

Because human preadipocytes grow and differentiate slowly and cannot be easily transfected (37), we used an established mouse preadipocyte cell line (3T3-L1 cells) (29, 30) instead as the cell model in all of the following experiments in order to investigate the cross-talk between Ang(1–7) and AngII signaling observed from human preadipocytes. We first confirmed that 3T3-L1 cells express Ang(1–7) receptor (Mas receptor) and AngII receptors (both AT1 and AT2 receptors) (Fig. 2A and supplemental Fig. S1) (38, 39).

FIGURE 2.
Ang(1–7) enhances adipogenesis of 3T3-L1 preadipocytes. A, confocal images of immunostained Mas receptor in 3T3-L1 preadipocyte and differentiated 3T3-L1 adipocyte (day 8). Scale bars, 10 μm. B, representative images of 3T3-L1 cells at ...

As 3T3-L1 preadipocytes were differentiating into adipocytes (day 0–6 after hormonal induction of differentiation), the expression of PPARγ, C/EBPα, FAS, ACC, and aP2 were significantly up-regulated, along with their morphological change and increased intracellular accumulation of lipid droplets (Fig. 2). Consistent with the observations from human preadipocytes (Fig. 1), Ang(1–7) treatment during differentiation increased the expression of adipogenic markers (PPARγ, C/EBPα, FAS, ACC, and aP2), Oil Red O staining, and TG content (Fig. 2 and supplemental Fig. S3). Ang(1–7)-stimulated adipogenesis is apparently dose-dependent (supplemental Fig. S3).

In order to evaluate the role of AngII in adipogenesis of 3T3-L1 cells, we have to differentiate the effects mediated by the AT1 or AT2 receptor. This is achieved by challenging the AT2 siRNA knockdown 3T3-L1 cells or AT1 siRNA knockdown cells with AngII. Knockdown of the AT1 or AT2 gene (Agtr1 or Agtr2) was confirmed by Western blot analyses (supplemental Fig. S1). As shown in Fig. 3, activation of AT1 receptors decreased Oil Red O staining, TG content, and expression of all adipogenic markers (PPARγ, C/EBPα, FAS, ACC, and aP2), whereas AT2 activation did the opposite. These results were corroborated in naive 3T3-L1 cells by selective inhibition of AT1 or AT2 using their specific antagonists (supplemental Fig. S4). These experiments establish the inhibitory role of AngII-AT1 signaling in adipogenesis, which is in agreement with previous reports (1921) and our observations in human preadipocytes (Fig. 1). Also similar to the observations from human preadipocytes (Fig. 1), co-incubation of Ang(1–7) essentially reversed the inhibitory effects of AT1 receptor activation upon adipogenesis. On the other hand, Ang(1–7) did not affect AT2-stimulated adipogenesis (Fig. 3 and supplemental Fig. S4). Taken together, we show that 3T3-L1 is a good and convenient alternative model to human preadipocytes to study the stimulatory roles of Ang(1–7)-Mas signaling in adipogenesis and its cross-talk with AngII-AT1 pathways.

FIGURE 3.
Ang(1–7) stimulates adipogenesis and neutralizes the antiadipogenic effect of AngII-AT1 receptor activation in 3T3-L1 preadipocytes. The cells were transfected with control siRNA or AT1 receptor siRNA or AT2 receptor siRNA and cultured until confluence. ...

Autocrine Interplays between Ang(1–7) and AngII

It is known that production of AngII and its precursor peptide (angiotensinogen) increases during adipogenesis (20, 40). AngII peptides, in turn, are cleaved by a membrane-bound ectoenzyme (ACE2) to form Ang(1–7) (4). It is thus conceivable that Ang(1–7) production might increase as well during adipogenesis. Indeed, as shown in Fig. 4, A and B, both Ang(1–7) and AngII released into the culture media were elevated during adipogenesis. Because the receptors for Ang(1–7) and AngII are expressed in preadipocytes and adipocytes (12, 39) (Figs. 1 and and22 and supplemental Fig. S1), it is likely that these locally produced Ang(1–7) and AngII may serve as the autocrine feedback signals upon adipocyte differentiation in an interactive way.

FIGURE 4.
Autocrine interplays between Ang(1–7) and AngII in the differentiation of 3T3-L1 preadipocytes. The cells were transfected with control siRNA or ACE2 siRNA, and cultured until confluence. This was followed by 7–8 days of differentiation, ...

Ace2 gene expression in 3T3-L1 cells was blocked by specific ACE2 siRNA before the initiation of differentiation (verified by Western blot analyses shown in supplemental Fig. S1). As a result, it was found that the release of Ang(1–7) from these cells was considerably lowered throughout the differentiation, whereas the AngII release was increased in the early stage (day 1–2) (Fig. 4, A and B). It was also noted that adipogenesis was suppressed in ACE2 siRNA knockdown cells, as evidenced by the reduced number of lipid-laden adipocytes and decreased expression of adipocyte markers: aP2 and FAS (Fig. 4, C–F). This is presumably due to the decrease of the adipogenic factor Ang(1–7) and increase of the antiadipogenic factor AngII. In support of this, we show that down-regulation of adipogenesis by ACE2 knockdown can be effectively rectified by application of Ang(1–7) or blocking of the AT1 receptor. These results demonstrate that ACE2 is a critical linker to control the balance between Ang(1–7) and AngII signaling.

Fig. 4, G and H, shows that ACE2 expression steadily increased over time during the 3T3-L1 differentiation, promoting adipogenesis by strengthening Ang(1–7) signaling. Intriguingly, exogenous application of Ang(1–7) suppressed the increase of ACE2 expression (Fig. 4G), whereas AngII-AT1 activation further enhanced ACE expression in the early differentiation phase (day 1). These observations suggest that a delicate balance is established by the interplays between AngII, ACE2, and Ang(1–7).

It is known that the antiadipogenic effect of AngII-AT1 involves the activation (phosphorylation) of ERK1/2 (19). Here, we show that Ang(1–7) neutralizes the antiadipogenic effect of AngII-AT1 by interfering with ERK1/2 activation because, in AT2 siRNA knockdown cells, AngII-enhanced ERK1/2 phosphorylation was abolished by co-incubation of Ang(1–7) (Fig. 4I). In summary, we provide evidence that the local autocrine regulations of Ang(1–7) and AngII play important and counteracting roles in adipogenesis, and the cross-talks between Ang(1–7)-Mas and AngII-AT1 signaling are linked by ACE2 and ERK1/2.

Involvement of Mas Receptor

The experiments on human preadipocytes (Fig. 1) demonstrate that the adipogenic and anti-AngII effects of Ang(1–7) are mediated by the Mas receptor. Here, we further analyzed the involvement of the Mas receptor using Mas1 gene knockdown 3T3-L1 cells. The knockdown of Mas receptor expression by MAS1 siRNA was verified by Western blot analyses (supplemental Fig. S1).

In the Mas knockdown cells, the expressions of adipogenic markers (PPARγ, FAS, ACC, and aP2) were reduced (Fig. 5, A and B), and as expected, Ang(1–7) failed to increase the expression of these markers and to abolish the inhibition by AngII. Some studies have reported low affinity interaction of Ang(1–7) with AT1 and AT2 receptors in other cell types (41, 42). To rule out the possible contributions from AT1 and AT2 receptors, we show that Ang(1–7)-stimulated expression of the adipogenic markers was not compromised when AT1 and AT2 receptors were simultaneously blocked by their respective antagonists. These results establish that the adipogenic effects of Ang(1–7) are mediated by Mas receptors.

FIGURE 5.
Involvement of Mas receptor in 3T3-L1 adipogenesis. The cells were transfected with control siRNA or Mas receptor siRNA and cultured until confluence. Differentiation was then induced for 7–8 days, without (−) (control) or with (+) 1 μ ...

Furthermore, we also observed that Mas receptor expression increased over time during the 3T3-L1 differentiation, and application of exogenous Ang(1–7) elevated Mas receptor expression at the early differentiation phase (day 1–2) (Fig. 5C). These experiments demonstrate the positive regulation of Ang(1–7)-Mas signaling to accelerate adipogenesis, particularly in the early stage.

Stimulation of Adipogenesis by Ang(1–7) is MAPK Kinase/ERK- and PI3K/Akt-dependent

Next, we explored the signaling pathways responsible for the stimulatory effect of Ang(1–7) on adipogenesis of 3T3-L1 cells. It is known that the phosphorylation (activation) of ERK1/2 is required for mitotic clonal expansion in the early stage of adipogenesis (43, 44); however, ERK1/2 activity must quickly return to a low level to avoid inactivation (phosphorylation) of the critical adipogenic factor (PPARγ) (45, 46). Indeed, as shown in Fig. 6A, hormonal stimulation of adipogenesis caused an acute increase of ERK1/2 phosphorylation (within 15 min), which was followed by a quick decay to a low level. Interestingly, such decay was exaggerated by the addition of Ang(1–7) (Fig. 6A). As discussed above, it would help to sustain the adipogenic process by preventing ERK1/2-induced inactivation (phosphorylation) of PPARγ. This is confirmed in Fig. 6B.

FIGURE 6.
Effects of Ang(1–7) on the phosphorylation of ERK1/2, PPARγ and Akt in 3T3-L1 cells during the early stage of differentiation. Shown are Western blot analyses of the phosphorylation and total protein levels of ERK1/2 (A), PPARγ ...

PI3K/Akt signaling-triggered PPARγ expression is also well known for its critical role in adipogenesis (47, 48). Regulation of Ang(1–7) on the PI3K/Akt pathway has been reported in other cell types (49, 50). As shown in Fig. 6C, phosphorylation of Akt was acutely induced (within 5 min) upon induction of adipogenic differentiation, and this acute phosphorylation was largely enhanced by the addition of Ang(1–7), although such enhancement is short lived (within 15 min).

ERK1/2 and Akt are the substrates of MAPK kinase and PI3K, respectively. Stimulation of MAPK kinase by phorbol 12-myristate 13-acetate (PMA) produced a significant inhibitory effect on adipogenesis, as evidenced by the reduced number of mature adipocytes and expression of adipogenic markers (aP2, FAS, ACC, and PPARγ) (Fig. 7, A–G). On the contrary, inhibiting MAPK kinase by PD98059 (51) slightly enhanced adipogenesis (Fig. 7 and supplemental Fig. S5). PD98059 inhibition and PMA stimulation upon adipogenesis have also been reported previously (5254). Here, we further show that PMA was able to partially eliminate Ang(1–7)-induced adipogenesis (Fig. 7 and supplemental Fig. S5). In another line of experiments, it was found that blocking PI3K by LY294002 (55) significantly inhibited adipogenesis and abolished the stimulatory effect of Ang(1–7) (Fig. 7, A–G).

FIGURE 7.
Effect of PI3K/Akt and MAPK kinase/ERK signaling pathways on Ang(1–7)-induced adipogenesis of 3T3-L1 cells. The cells were induced to differentiate for 7–8 days without (control) or with 1 μm Ang(1–7), 10 μm LY294002 ...

The ERK1/2 inhibition and Akt stimulation upon adipogenesis were further confirmed by knockdown of ERK1/2 (Mapk3 and Mapk1) or Akt1/2 genes before the initiation of 3T3-L1 cell differentiation. The knockdown of the protein expression was verified by Western blot (supplemental Fig. S5). In the ERK1/2 knockdown cells, the expressions of adipogenic markers (aP2 and FAS) were significantly increased, whereas in the Akt knockdown cells, the expressions of these markers were largely suppressed (Fig. 7, H–J). Also, as expected, Ang(1–7) failed to increase the expressions of these markers in the Akt knockdown cells (Fig. 7, H–J).

Taken together, it may be concluded that Ang(1–7) stimulates adipogenesis through two distinct pathways: 1) inhibiting MAPK kinase-ERK1/2 signaling, which leads to PPARγ inactivation, and 2) enhancing PI3K/Akt signaling, which leads to PPARγ expression. The latter pathway appears to be more potent.

Ang(1–7) Acts in the Early Stage of Differentiation

The acute action of Ang(1–7) on ERK1/2 and Akt phosphorylation (shown in Fig. 6) suggests the importance of Ang(1–7) signaling in the early stage of differentiation. In support of this view, it was found, based on the number of differentiated adipocytes and expressions of adipogenic markers (aP2 and FAS), that administration of Ang(1–7) even 1 day after the hormonal initiation of differentiation failed to stimulate adipogenesis, whereas incubation with Ang(1–7) only for the first day of differentiation was as potent as its presence for the whole differentiation process (6 days) (Fig. 8).

FIGURE 8.
Ang(1–7) exerts its stimulatory effect on adipogenesis in the early stage of differentiation. 3T3-L1 cells were induced to differentiate without (control) or with exposure to 1 μm Ang(1–7) for different periods of time: from day ...

To further confirm that Ang(1–7) acts mainly on the early stage of differentiation, the Mas receptor was knocked down at different stages of differentiation (at day −2 (2 days before the initiation of differentiation) or at day 0, day 2, or day 4) (Fig. 8, G–I). The Mas receptor expression was largely suppressed even 1 day after the transfection with MAS1 siRNA, which was verified by Western blot analyses (supplemental Fig. S1). Consistent with our data shown in Fig. 5, Ang(1–7) failed to increase the expression of adipogenic markers (aP2 and FAS) in the 3T3-L1 cells transfected with MAS1 siRNA at day −2; however, Ang(1–7) was able to significantly stimulate the expressions of these markers in the cells transfected with MAS1 siRNA at day 0, day 2, or day 4 (Fig. 8, G–I).

It is known that, in the early stage of differentiation, preadipocytes undergo several rounds of cell division, known as mitotic clonal expansion, before undertaking terminal differentiation, through which they acquire the characteristics of maturity (33, 43). We show in Fig. 8C that induction of differentiation resulted in 2–3-fold increase in cell number within 2 days, but Ang(1–7) treatment had an insignificant effect on cell proliferation. This observation rules out the possibility that the adipogenic effects of Ang(1–7) is due to increased mitotic clonal expansion.

DISCUSSION

Adipocytes, which were previously regarded as the passive storage depots for excess energy (fat), actually play perplexing and integrative roles in regulating metabolism (56). Complicated cross-talks exist between adipocytes and other cells in the metabolic networks (57). For example, the functions of adipocytes (adipogenesis, lipid, and carbohydrate metabolism) are highly regulated by insulin secreted by pancreatic beta cells (58), catecholamines secreted by chromaffin cells (59), and glucocorticoid secreted by adrenal cortex (60). On the other hand, adipocytes release a variety of adipokines (e.g. leptin, apelin, and AngII) to control various aspects of metabolism and influence the secretion of other metabolic factors or hormones from other cells (59, 61). Intriguingly, the receptors of some adipokines are identified in adipocytes, implying the existence of autocrine regulatory loops on adipocyte functions (39, 62, 63). For instance, adiponectin-adiponectin receptor (AdipoR1 and AdipoR2) promotes adipogenesis and insulin-induced glucose uptake and inhibits lipolysis (64, 65); leptin-leptin receptor (ObR) inhibits adipogenesis and glucose uptake and promotes lipolysis (54, 66); and apelin-apelin receptor inhibits adipogenesis and lipolysis (26) and promotes insulin sensitivity and glucose uptake (67).

In this study, we demonstrate the local autocrine regulation by the angiotensin system. Specifically, the counteracting interplays between Ang(1–7)-Mas and AngII-AT1 signaling upon adipogenesis are revealed, as illustrated in Fig. 9, Based on our experiments and the previous reports (5, 19, 45, 48), the following scenario may be proposed. During adipogenesis, the production of AngII (Fig. 4) and AT1 receptor is up-regulated (20, 40), acting as a dampening feedback (Figs. 1 and and3).3). Local accumulation of AngII stimulates the expression of ACE2 and production of Ang(1–7) by ACE2 (Fig. 4). Mediated by Mas receptor, Ang(1–7), in turn, enhances adipogenesis (Figs. 115) by inhibiting the AngII-AT1-triggered MAPK kinase-ERK1/2 pathway to activate the adipogenic factor PPARγ (Figs. 4, ,6,6, and and7)7) and by stimulating the PI3K/Akt pathway to increase PPARγ expression (Figs. 6 and and7).7). This action is further augmented by Ang(1–7)-induced Mas receptor expression (Fig. 5). Ang(1–7), on the other hand, reduces ACE2 expression presumably to avoid overproduction of Ang(1–7) (Fig. 4). As described, multilateral negative and positive feedback loops peculiarly co-exist. Presumably, such complex interplays are balanced to ensure appropriate pace and phasing in differentiation. Disruption of these subtle interplays by silencing ACE2 expression or Mas receptor expression freezes adipogenesis, whereas the addition of exogenous Ang(1–7) accelerates adipogenesis.

FIGURE 9.
Illustration of the interplays between Ang(1–7)-Mas and AngII-AT1 signaling in adipogenesis.

It is increasingly accepted that formation of new adipocytes (adipogenesis) is a physiological adaptive response to excessive calorie intake in order to maintain an overall healthier adipose tissue because newly differentiated adipocytes are more insulin-sensitive (thus more capable of energy storage) (68, 69). Otherwise, hypertrophic adipocytes, which are less insulin-sensitive, will result (70, 71). The adverse metabolic consequences of enlarged adipocytes (particularly in visceral fat) have been extensively documented, including insulin resistance-caused type 2 diabetes and hypertriglyceridemia (72, 73). The adipogenic potential of preadipocytes from different fat depots differs. Subcutaneous preadipocytes are more sensitive to the adipogenic stimuli (e.g. PPARγ agonist) than visceral ones (74, 75). Adipogenesis in subcutaneous adipose tissues thus assists in preventing the notorious hypertrophy of visceral adipose (76). Therefore, the adipogenic effect of Ang(1–7) signaling should, albeit counterintuitively, be beneficial. This is supported by previous studies on animal models. For instance, increasing the circulating level of Ang(1–7) in rats improves insulin sensitivity in adipose tissue and decreases the plasma level of triglyceride and visceral fat mass (7, 77), whereas knockdown of Mas receptors in mice results in impaired insulin sensitivity and increased visceral fat mass (78). In contrast, the antiadipogenic AngII-AT1 signaling increases visceral adipose tissue growth and insulin resistance (19, 79, 80), whereas administration of AT1 receptor blockers reduces fat mass and improves insulin sensitivity in human and several animal models (8183).

Through circulation, the autocrine balance between AngII and Ang(1–7) signaling can be influenced by other angiotensin-peptide producing cells (e.g. vascular endothelial and smooth muscle cells, cardiac myocytes, pancreatic beta cells, hepatocytes, etc.) (2, 6). On the other hand, adipose tissue is a major source of angiotensin peptides (10, 84), which play critical roles in regulating, for example, blood vessel contraction (85), angiogenesis (86), glucose uptake in skeletal muscles (9), and hormone secretion (39, 87). Such cross-talks may underlie the association between obesity and other metabolic disorders (e.g. diabetes and cardiovascular diseases). Hence, this study not only reveals the intriguing autocrine interplays between AngII and Ang(1–7) signaling upon adipogenesis but also raises the possibility of targeting these molecular pathways to treat metabolic disorders.

Supplementary Material

Supplemental Data:

*This work was supported by the Singapore Ministry of Health National Medical Research Council under its EDG grant (NMRC/EDG/1048/2011).

An external file that holds a picture, illustration, etc.
Object name is sbox.jpgThis article contains supplemental Figs. S1–S5.

2The abbreviations used are:

RAS
renin-angiotensin system
AngII
angiotensin II
Ang(1–7)
angiotensin 1–7
ACE
angiotensin-converting enzyme
AT1
AngII type 1 receptor
AT2
AngII type 2 receptor
Akt
protein kinase B
ACC
acetyl-CoA carboxylase
aP2
adipocyte protein 2
C/EBP
CCAAT/enhancer-binding protein
FAS
fatty acid synthase
PPAR
peroxisome proliferator-activated receptor
PMA
phorbol 12-myristate 13-acetate.

REFERENCES

1. Cleland S. J., Reid J. L. (1996) The renin-angiotensin system and the heart. A historical review. Heart 76, 7–12 [PMC free article] [PubMed]
2. Paul M., Poyan Mehr A., Kreutz R. (2006) Physiology of local renin-angiotensin systems. Physiol. Rev. 86, 747–803 [PubMed]
3. Dinh D. T., Frauman A. G., Johnston C. I., Fabiani M. E. (2001) Angiotensin receptors. Distribution, signalling and function. Clin. Sci. 100, 481–492 [PubMed]
4. Clarke N. E., Turner A. J. (2012) Angiotensin-converting enzyme 2. The first decade. Int. J. Hypertens. 2012, 307315. [PMC free article] [PubMed]
5. Santos R. A., Simoes e Silva A. C., Maric C., Silva D. M., Machado R. P., de Buhr I., Heringer-Walther S., Pinheiro S. V., Lopes M. T., Bader M., Mendes E. P., Lemos V. S., Campagnole-Santos M. J., Schultheiss H. P., Speth R., Walther T. (2003) Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258–8263 [PubMed]
6. Santos R. A., Ferreira A. J., Verano-Braga T., Bader M. (2013) Angiotensin-converting enzyme 2, Angiotensin-(1–7) and Mas. New players of the renin angiotensin system. J. Endocrinol. 216, R1–R17 [PubMed]
7. Santos S. H., Braga J. F., Mario E. G., Pôrto L. C., Rodrigues-Machado Mda G., Murari A., Botion L. M., Alenina N., Bader M., Santos R. A. (2010) Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1–7). Arterioscler. Thromb. Vasc. Biol. 30, 953–961 [PubMed]
8. de Kloet A. D., Krause E. G., Woods S. C. (2010) The renin angiotensin system and the metabolic syndrome. Physiol. Behav. 100, 525–534 [PMC free article] [PubMed]
9. Kalupahana N. S., Moustaid-Moussa N. (2012) The renin-angiotensin system. A link between obesity, inflammation and insulin resistance. Obes. Rev. 13, 136–149 [PubMed]
10. Cassis L. A., Police S. B., Yiannikouris F., Thatcher S. E. (2008) Local adipose tissue renin-angiotensin system. Curr. Hypertens. Rep. 10, 93–98 [PMC free article] [PubMed]
11. Kalupahana N. S., Moustaid-Moussa N. (2012) The adipose tissue renin-angiotensin system and metabolic disorders. A review of molecular mechanisms. Crit. Rev. Biochem. Mol. Biol. 47, 379–390 [PubMed]
12. Gupte M., Boustany-Kari C. M., Bharadwaj K., Police S., Thatcher S., Gong M. C., English V. L., Cassis L. A. (2008) ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295, R781–R788 [PubMed]
13. Engeli S., Gorzelniak K., Kreutz R., Runkel N., Distler A., Sharma A. M. (1999) Co-expression of renin-angiotensin system genes in human adipose tissue. J. Hypertens. 17, 555–560 [PubMed]
14. Goossens G. H., Blaak E. E., Arner P., Saris W. H., van Baak M. A. (2007) Angiotensin II. A hormone that affects lipid metabolism in adipose tissue. Int. J. Obes. 31, 382–384 [PubMed]
15. Fujimoto M., Masuzaki H., Tanaka T., Yasue S., Tomita T., Okazawa K., Fujikura J., Chusho H., Ebihara K., Hayashi T., Hosoda K., Nakao K. (2004) An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576, 492–497 [PubMed]
16. Oh Y. B., Kim J. H., Park B. M., Park B. H., Kim S. H. (2012) Captopril intake decreases body weight gain via angiotensin-(1–7). Peptides 37, 79–85 [PubMed]
17. Liu C., Lv X. H., Li H. X., Cao X., Zhang F., Wang L., Yu M., Yang J. K. (2012) Angiotensin-(1–7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes. Acta Diabetol. 49, 291–299 [PubMed]
18. Kurata A., Nishizawa H., Kihara S., Maeda N., Sonoda M., Okada T., Ohashi K., Hibuse T., Fujita K., Yasui A., Hiuge A., Kumada M., Kuriyama H., Shimomura I., Funahashi T. (2006) Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 70, 1717–1724 [PubMed]
19. Fuentes P., Acuña M. J., Cifuentes M., Rojas C. V. (2010) The anti-adipogenic effect of angiotensin II on human preadipose cells involves ERK1,2 activation and PPARG phosphorylation. J. Endocrinol. 206, 75–83 [PubMed]
20. Janke J., Engeli S., Gorzelniak K., Luft F. C., Sharma A. M. (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51, 1699–1707 [PubMed]
21. Brücher R., Cifuentes M., Acuña M. J., Albala C., Rojas C. V. (2007) Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans. Obesity 15, 1643–1646 [PubMed]
22. Tomlinson J. J., Boudreau A., Wu D., Abdou Salem H., Carrigan A., Gagnon A., Mears A. J., Sorisky A., Atlas E., Haché R. J. (2010) Insulin sensitization of human preadipocytes through glucocorticoid hormone induction of forkhead transcription factors. Mol. Endocrinol. 24, 104–113 [PubMed]
23. Hemmrich K., von Heimburg D., Cierpka K., Haydarlioglu S., Pallua N. (2005) Optimization of the differentiation of human preadipocytes in vitro. Differentiation 73, 28–35 [PubMed]
24. Gregoire F. M., Smas C. M., Sul H. S. (1998) Understanding adipocyte differentiation. Physiol. Rev. 78, 783–809 [PubMed]
25. Ye F., Zhang H., Yang Y. X., Hu H. D., Sze S. K., Meng W., Qian J., Ren H., Yang B. L., Luo M. Y., Wu X., Zhu W., Cai W. J., Tong J. B. (2011) Comparative proteome analysis of 3T3-L1 adipocyte differentiation using iTRAQ-coupled 2D LC-MS/MS. J. Cell Biochem. 112, 3002–3014 [PubMed]
26. Than A., Cheng Y., Foh L. C., Leow M. K., Lim S. C., Chuah Y. J., Kang Y., Chen P. (2012) Apelin inhibits adipogenesis and lipolysis through distinct molecular pathways. Mol. Cell Endocrinol. 362, 227–241 [PubMed]
27. Hashimoto T., Igarashi J., Kosaka H. (2009) Sphingosine kinase is induced in mouse 3T3-L1 cells and promotes adipogenesis. J. Lipid Res. 50, 602–610 [PMC free article] [PubMed]
28. Ramírez-Zacarías J. L., Castro-Muñozledo F., Kuri-Harcuch W. (1992) Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 97, 493–497 [PubMed]
29. Poulos S. P., Dodson M. V., Hausman G. J. (2010) Cell line models for differentiation. Preadipocytes and adipocytes. Exp. Biol. Med. 235, 1185–1193 [PubMed]
30. Rosen E. D., Walkey C. J., Puigserver P., Spiegelman B. M. (2000) Transcriptional regulation of adipogenesis. Genes Dev. 14, 1293–1307 [PubMed]
31. Schling P., Mallow H., Trindl A., Löffler G. (1999) Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int. J. Obes. Relat. Metab. Disord. 23, 336–341 [PubMed]
32. Lowell B. B. (1999) PPARγ. An essential regulator of adipogenesis and modulator of fat cell function. Cell 99, 239–242 [PubMed]
33. Rosen E. D., Spiegelman B. M. (2000) Molecular regulation of adipogenesis. Annu. Rev. Cell Dev. Biol. 16, 145–171 [PubMed]
34. Krämer B. K., Ritthaler T., Schweda F., Ittner K. P., Scholz H., Riegger G. A., Kurtz A. (1998) Effects of the angiotensin II type-1 receptor antagonist ZD7155 on angiotensin II-mediated regulation of renin secretion and renal renin gene expression, renal vasoconstriction, and blood pressure in rats. J. Cardiovasc. Pharmacol. 31, 700–705 [PubMed]
35. Blankley C. J., Hodges J. C., Klutchko S. R., Himmelsbach R. J., Chucholowski A., Connolly C. J., Neergaard S. J., Van Nieuwenhze M. S., Sebastian A., Quin J., 3rd (1991) Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J. Med. Chem. 34, 3248–3260 [PubMed]
36. Santos R. A., Campagnole-Santos M. J., Baracho N. C., Fontes M. A., Silva L. C., Neves L. A., Oliveira D. R., Caligiorne S. M., Rodrigues A. R., Gropen Júnior C. (1994) Characterization of a new angiotensin antagonist selective for angiotensin-(1–7): evidence that the actions of angiotensin-(1–7) are mediated by specific angiotensin receptors. Brain Res. Bull. 35, 293–298 [PubMed]
37. Hutley L., Shurety W., Newell F., McGeary R., Pelton N., Grant J., Herington A., Cameron D., Whitehead J., Prins J. (2004) Fibroblast growth factor 1. A key regulator of human adipogenesis. Diabetes 53, 3097–3106 [PubMed]
38. Mallow H., Trindl A., Löffler G. (2000) Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes. Horm. Metab. Res. 32, 500–503 [PubMed]
39. Than A., Tee W. T., Chen P. (2012) Apelin secretion and expression of apelin receptors in 3T3-L1 adipocytes are differentially regulated by angiotensin type 1 and type 2 receptors. Mol. Cell Endocrinol. 351, 296–305 [PubMed]
40. Hung W. W., Hsieh T. J., Lin T., Chou P. C., Hsiao P. J., Lin K. D., Shin S. J. (2011) Blockade of the renin-angiotensin system ameliorates apelin production in 3T3-L1 adipocytes. Cardiovasc. Drugs Ther. 25, 3–12 [PubMed]
41. Rowe B. P., Saylor D. L., Speth R. C., Absher D. R. (1995) Angiotensin-(1–7) binding at angiotensin II receptors in the rat brain. Regul. Pept. 56, 139–146 [PubMed]
42. Castro C. H., Santos R. A., Ferreira A. J., Bader M., Alenina N., Almeida A. P. (2005) Evidence for a functional interaction of the angiotensin-(1–7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 46, 937–942 [PubMed]
43. Tang Q. Q., Otto T. C., Lane M. D. (2003) Mitotic clonal expansion. A synchronous process required for adipogenesis. Proc. Natl. Acad. Sci. U.S.A. 100, 44–49 [PubMed]
44. Qiu Z., Wei Y., Chen N., Jiang M., Wu J., Liao K. (2001) DNA synthesis and mitotic clonal expansion is not a required step for 3T3-L1 preadipocyte differentiation into adipocytes. J. Biol. Chem. 276, 11988–11995 [PubMed]
45. Bost F., Aouadi M., Caron L., Binétruy B. (2005) The role of MAPKs in adipocyte differentiation and obesity. Biochimie 87, 51–56 [PubMed]
46. Adams M., Reginato M. J., Shao D., Lazar M. A., Chatterjee V. K. (1997) Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272, 5128–5132 [PubMed]
47. Xu J., Liao K. (2004) Protein kinase B/AKT 1 plays a pivotal role in insulin-like growth factor-1 receptor signaling induced 3T3-L1 adipocyte differentiation. J. Biol. Chem. 279, 35914–35922 [PubMed]
48. Sakaue H., Ogawa W., Matsumoto M., Kuroda S., Takata M., Sugimoto T., Spiegelman B. M., Kasuga M. (1998) Posttranscriptional control of adipocyte differentiation through activation of phosphoinositide 3-kinase. J. Biol. Chem. 273, 28945–28952 [PubMed]
49. Giani J. F., Gironacci M. M., Muñoz M. C., Peña C., Turyn D., Dominici F. P. (2007) Angiotensin-(1–7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo. Role of the AT1 and Mas receptors. Am. J. Physiol. Heart Circ. Physiol. 293, H1154–H1163 [PubMed]
50. Sampaio W. O., Souza dos Santos R. A., Faria-Silva R., da Mata Machado L. T., Schiffrin E. L., Touyz R. M. (2007) Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49, 185–192 [PubMed]
51. Alessi D. R., Cuenda A., Cohen P., Dudley D. T., Saltiel A. R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489–27494 [PubMed]
52. Dang Z. C., Lowik C. W. (2004) Differential effects of PD98059 and U0126 on osteogenesis and adipogenesis. J. Cell Biochem. 92, 525–533 [PubMed]
53. Xu L., Nishimura K., Jisaka M., Nagaya T., Yokota K. (2006) Gene expression of arachidonate cyclooxygenase pathway leading to the delayed synthesis of prostaglandins E2 and F2α in response to phorbol 12-myristate 13-acetate and action of these prostanoids during life cycle of adipocytes. Biochim. Biophys. Acta. 1761, 434–444 [PubMed]
54. Rhee S. D., Sung Y. Y., Jung W. H., Cheon H. G. (2008) Leptin inhibits rosiglitazone-induced adipogenesis in murine primary adipocytes. Mol. Cell Endocrinol. 294, 61–69 [PubMed]
55. Vlahos C. J., Matter W. F., Hui K. Y., Brown R. F. (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241–5248 [PubMed]
56. Frühbeck G., Gómez-Ambrosi J., Muruzábal F. J., Burrell M. A. (2001) The adipocyte. A model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 280, E827–E847 [PubMed]
57. Schling P., Löffler G. (2002) Cross talk between adipose tissue cells. Impact on pathophysiology. News Physiol. Sci. 17, 99–104 [PubMed]
58. Attie A. D., Scherer P. E. (2009) Adipocyte metabolism and obesity. J. Lipid Res. 50, S395–S399 [PMC free article] [PubMed]
59. Than A., Ye F., Xue R., Ong J. W., Poh C. L., Chen P. (2011) The crosstalks between adipokines and catecholamines. Mol. Cell Endocrinol. 332, 261–270 [PubMed]
60. Peckett A. J., Wright D. C., Riddell M. C. (2011) The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism 60, 1500–1510 [PubMed]
61. Guerre-Millo M. (2004) Adipose tissue and adipokines. For better or worse. Diabetes Metab. 30, 13–19 [PubMed]
62. Karastergiou K., Mohamed-Ali V. (2010) The autocrine and paracrine roles of adipokines. Mol. Cell Endocrinol. 318, 69–78 [PubMed]
63. Ye F., Than A., Zhao Y., Goh K. H., Chen P. (2010) Vesicular storage, vesicle trafficking, and secretion of leptin and resistin. The similarities, differences, and interplays. J. Endocrinol. 206, 27–36 [PubMed]
64. Fu Y., Luo N., Klein R. L., Garvey W. T. (2005) Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J. Lipid Res. 46, 1369–1379 [PubMed]
65. Qiao L., Kinney B., Schaack J., Shao J. (2011) Adiponectin inhibits lipolysis in mouse adipocytes. Diabetes 60, 1519–1527 [PMC free article] [PubMed]
66. Frühbeck G., Aguado M., Martínez J. A. (1997) In vitro lipolytic effect of leptin on mouse adipocytes. Evidence for a possible autocrine/paracrine role of leptin. Biochem. Biophys. Res. Commun. 240, 590–594 [PubMed]
67. Zhu S., Sun F., Li W., Cao Y., Wang C., Wang Y., Liang D., Zhang R., Zhang S., Wang H., Cao F. (2011) Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes. Mol. Cell Biochem. 353, 305–313 [PubMed]
68. Danforth E., Jr. (2000) Failure of adipocyte differentiation causes type II diabetes mellitus? Nat. Genet. 26, 13. [PubMed]
69. Freedland E. S. (2004) Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome. Implications for controlling dietary carbohydrates. A review. Nutr. Metab. 1, 12 [PMC free article] [PubMed]
70. Jernås M., Palming J., Sjöholm K., Jennische E., Svensson P. A., Gabrielsson B. G., Levin M., Sjögren A., Rudemo M., Lystig T. C., Carlsson B., Carlsson L. M., Lönn M. (2006) Separation of human adipocytes by size. Hypertrophic fat cells display distinct gene expression. FASEB J. 20, 1540–1542 [PubMed]
71. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., Satoh S., Nakano R., Ishii C., Sugiyama T., Eto K., Tsubamoto Y., Okuno A., Murakami K., Sekihara H., Hasegawa G., Naito M., Toyoshima Y., Tanaka S., Shiota K., Kitamura T., Fujita T., Ezaki O., Aizawa S., Kadowaki T. (1999) PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597–609 [PubMed]
72. Lebovitz H. E., Banerji M. A. (2005) Point. Visceral adiposity is causally related to insulin resistance. Diabetes Care 28, 2322–2325 [PubMed]
73. Miller M., Stone N. J., Ballantyne C., Bittner V., Criqui M. H., Ginsberg H. N., Goldberg A. C., Howard W. J., Jacobson M. S., Kris-Etherton P. M., Lennie T. A., Levi M., Mazzone T., Pennathur S. (2011) Triglycerides and cardiovascular disease. A scientific statement from the American Heart Association. Circulation 123, 2292–2333 [PubMed]
74. Ibrahim M. M. (2010) Subcutaneous and visceral adipose tissue. Structural and functional differences. Obes. Rev. 11, 11–18 [PubMed]
75. Adams M., Montague C. T., Prins J. B., Holder J. C., Smith S. A., Sanders L., Digby J. E., Sewter C. P., Lazar M. A., Chatterjee V. K., O'Rahilly S. (1997) Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100, 3149–3153 [PMC free article] [PubMed]
76. Laplante M., Festuccia W.T., Soucy G., Gélinas Y., Lalonde J., Berger J. P., Deshaies Y. (2006) Mechanisms of the depot specificity of peroxisome proliferator-activated receptor γ action on adipose tissue metabolism. Diabetes 55, 2771–2778 [PubMed]
77. Giani J. F., Mayer M. A., Muñoz M. C., Silberman E. A., Höcht C., Taira C. A., Gironacci M. M., Turyn D., Dominici F. P. (2009) Chronic infusion of angiotensin-(1–7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am. J. Physiol. Endocrinol. Metab. 296, E262–271 [PubMed]
78. Santos S. H., Fernandes L. R., Mario E. G., Ferreira A. V., Pôrto L. C., Alvarez-Leite J. I., Botion L. M., Bader M., Alenina N., Santos R. A. (2008) Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57, 340–347 [PubMed]
79. Sarzani R., Marcucci P., Salvi F., Bordicchia M., Espinosa E., Mucci L., Lorenzetti B., Minardi D., Muzzonigro G., Dessi-Fulgheri P., Rappelli A. (2008) Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int. J. Obes. 32, 259–267 [PubMed]
80. Olivares-Reyes J. A., Arellano-Plancarte A., Castillo-Hernandez J. R. (2009) Angiotensin II and the development of insulin resistance. Implications for diabetes. Mol. Cell Endocrinol. 302, 128–139 [PubMed]
81. He H., Yang D., Ma L., Luo Z., Ma S., Feng X., Cao T., Yan Z., Liu D., Tepel M., Zhu Z. (2010) Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-δ-dependent pathways. Hypertension 55, 869–879 [PubMed]
82. Kakuma T., Gotoh K., Masaki T., Itateyama E., Abe N., Yoshimatsu H. (2010) Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome. Obes. Res. Clin. Pract. 4, e145–e152 [PubMed]
83. Henriksen E. J., Jacob S., Kinnick T. R., Teachey M. K., Krekler M. (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38, 884–890 [PubMed]
84. Engeli S., Negrel R., Sharma A. M. (2000) Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35, 1270–1277 [PubMed]
85. Thatcher S., Yiannikouris F., Gupte M., Cassis L. (2009) The adipose renin-angiotensin system. Role in cardiovascular disease. Mol. Cell Endocrinol. 302, 111–117 [PMC free article] [PubMed]
86. Heffelfinger S. C. (2007) The renin angiotensin system in the regulation of angiogenesis. Curr. Pharm. Des. 13, 1215–1229 [PubMed]
87. Ramracheya R. D., Muller D. S., Wu Y., Whitehouse B. J., Huang G. C., Amiel S. A., Karalliedde J., Viberti G., Jones P. M., Persaud S. J. (2006) Direct regulation of insulin secretion by angiotensin II in human islets of Langerhans. Diabetologia 49, 321–331 [PubMed]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology